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 Interleukin-6 (IL-6) may be considered the prototypic multifunctional 
cytokine. Indeed, this is reflected in the many names assigned to it before its final 
designation in 1987 [1]. Human IL-6 is a 26kDa glycoprotein produced by several 
cell types including macrophages and lymphocytes.  Macrophages, with T and B 
lymphocytes, and dendritic cells comprise an immune compartment that in joints 
of patients with rheumatoid arthritis (RA) replaces what was the subintimal layer 
of synovium [2]. IL-6 is able to degrade cartilage and erode bone [3], and it is 
responsible for the production of acute phase reactants such as C-reactive 
protein [4]. 
 In patients with RA, concentrations of IL-6 in serum correlate with disease 
activity and extent of joint damage, and reduction in disease activity after 
treatment with disease-modifying antirheumatic drugs (DMARDs) is associated 
with reductions in serum concentrations of IL-6 [5]. Several small clinical trials 
suggest efficacy of treatment of RA patients with antibody to IL-6 or its receptor 
[6]. In addition, IL-6 induces spinal cord injury in patients with immune mediated 
transverse myelitis [7], and it has been implicated in the immunopathogenesis of 
systemic lupus erythematosus [8]. Thus, inhibition of IL-6 production may be a 
useful strategy for treatment of patients with RA and other immune mediated 
diseases characterized by inflammation and tissue injury.  
 The Cannabis plant has been a source of medicinal preparations since the 
earliest written records on pharmacobotany [9]. A major obstacle to broad 
acceptance of cannabinoids as therapeutic agents is their psychoactive effects. A 
class of cannabinoids, the carboxyl tetrahydrocannabinols, which are metabolites 
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of tetrahydrocannabinol (THC), shows promise as therapeutic agents that are 
free of cannabimimetic central nervous system activity [10]. These compounds, 
called cannabinoid acids, include all the carboxylic acid metabolites of the 
cannabinoids and their synthetic analogs. One analog, 1’1’-dimethylheptyl-THC-
11-oic acid, termed ajulemic acid (AjA), is a potent antiinflammatory and 
analgesic agent in several animal models [11, 12]. In addition, AjA is not 
psychoactive in mice. In fact, AjA suppresses THC-induced catalepsy in mice 
(10). Moreover, administration of 80 mg/day AjA for 1 week to patients with 
neuropathic pain relieved symptoms and did not induce behavioral changes [13].  
 Oral administration of AjA to rats with adjuvant arthritis prevents joint 
tissue injury in this animal model [14]. AjA binds to and activates the nuclear 
receptor peroxisome proliferator activated receptor gamma (PPARγ) in vitro [15]. 
Therefore, we investigated the influence of AjA on IL-6 production by and release 
from human monocyte derived macrophages (MDM). We also examined the role 
of PPARγ in the mechanism of action of AjA.  
 
MATERIALS AND METHODS 
Reagents. AjA was obtained from Organix (Woburn, MA). Its purity was 
monitored on high-pressure liquid chromatography by comparison with material 
synthesized previously [16]. The sample was 97% chemically pure, and was 
>99% chirally pure in the R, R enantiomer. AjA was dissolved in DMSO, then 
diluted with minimal essential medium (MEM) 2% fetal bovine serum (FBS) to 
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achieve appropriate concentrations. The concentration of DMSO was kept 
constant at 0.3%. GW9662 and troglitazone were from Biomol Laboratories Inc. 
Establishment of Monocyte Derived Macrophages (MDM). Peripheral 
blood mononuclear cells (PBMC) were isolated by Ficoll-Hypaque density 
gradient centrifugation in the usual manner [17]. PBMC (107/mL) in RPMI-2% 
FBS were incubated overnight at 5% CO2 and 37ºC in 6 or 12 well tissue culture 
plates. Non-adherent cells were removed and media was replaced with RPMI 
containing 10%-15% FBS. Cultures were maintained for 4-6 days in a 5% CO2 
humidified incubator at 37ºC. Media was then replaced with RPMI-2% FBS or 
other defined media according to experimental protocol. Cells were exposed or 
not to AjA (3-30µM) for 60 min., then stimulated with 10ng/ml LPS. Cells were 
collected at 4hr for assessment of IL-6 gene expression, and supernatants were 
collected at 18-24hr for measurement of secreted IL-6. 
Measurement of IL-6 mRNA by the Hybridization/Colorimetric Assay. 
Quantikine mRNA (R&D Systems) is a colorimetric microplate method used to 
quantify cytokine-specific mRNA at low levels [18]. RNA samples were hybridized 
with mRNA-specific biotin-labeled “capture” probes in a microtiter plate. After the 
hybridization reaction was complete, samples were transferred to a streptavidin 
coated microtiter plate, and the RNA/probe complex was captured. Unbound 
material was washed away, and anti-digoxigenin alkaline phosphatase conjugate 
was added. Unbound conjugate was washed away, and substrate solution was 
added, followed by the addition of an amplification solution. Development of color 
is in proportion to the amount of IL-6 mRNA in the original sample. The reaction 
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was stopped, and the color intensity was measured with a standard plate reader 
at 490nm with background correction at 650nm. The minimal detectable level 
was 1.6amol/mL. Conditions were run in triplicate. 
 Measurement of IL-6 Protein. Supernatants were collected and analyzed 
for IL-6 by ELISA (R&D). Standards and diluted samples were incubated for 2hr 
at room temperature and then washed. Substrate solution was added to the 
samples for 30 min. Samples were then read on a microplate reader at 450nm 
with background correction at 540nm. The minimal detectable level was 
3.1pg/ml.  Conditions were run in triplicate.  
 Viability of Cells. The integrity of the MDM at the end of experiments was 
assessed by exclusion of trypan blue. Cells were diluted in 0.5% trypan blue. 
Nonviable cells lost their ability to exclude trypan blue, and stained blue. In no 
instance did the proportion of nonviable cells exceed 5%. 
 Statistical Analysis. Data were analyzed and compared by paired 
Student’s test or by Student’s t-test difference of means of independent groups. 
 
RESULTS AND DISCUSSION 
 Release of IL-6 from MDM stimulated with LPS in vitro was suppressed by 
AjA in a dose dependent manner (Figure 1). In a series of 5 experiments, IL-6 
secretion was reduced 69.1+6.0% (mean+sd) by 10µM AjA (p=0.001 vs control 
cells not exposed to AjA).  Similarly, reduction by AjA of IL-6 gene expression 
was significant and dose dependent (Figure 2).  
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 We then tested the possibility of PPARγ dependence by exposure of 
human MDM to the irreversible PPARγ antagonist GW9662. AjA suppressed IL-6 
release from LPS stimulated cells whether or not PPARγ activity was blocked by 
GW9662. In addition, the known PPARγ activator troglitazone [19] did not 
suppress IL-6 release, and suppression of IL-6 release by AjA was not blocked 
by GW9662 (Table 1). The results suggest that the action of AjA on IL-6 
secretion from human MDM is PPARγ independent. 
Blockade of inflammatory cytokines such as tumor necrosis factor-α and 
interleukin 1β (IL-1β) is an effective strategy for the treatment of RA [20]. 
Interleukin-6 is a cytokine which can help maintain synovial inflammation and 
facilitate bone erosion [21, 22], and blockade of IL-6 action appears to be 
beneficial in treatment of patients with active RA [6]. In addition, a functional IL-6 
gene is necessary for development of type II collagen induced arthritis in mice 
[23], and blockade of IL-6 prevents establishment of antigen-induced arthritis in 
mice [24]. 
Results of experiments presented here indicate that addition of AjA to 
human MDM in vitro reduces steady state levels of IL-6 mRNA and the 
subsequent secretion of IL-6 from activated cells. Similar results were obtained 
with human PBMC and synovial fibroblasts (not shown). However, the influence 
of AjA on MDM IL-6 was much more consistent, perhaps because of the greater 
homogeneity of the cell system. Experiments done with MDM in which PPARγ 
activity was blocked indicate that suppression of IL-6 by AjA does not depend on 
PPARγ activation. In addition, the known selective PPARγ agonist, troglitazone, 
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does not suppress IL-6 release. Other PPARγ ligands such as prostaglandin J2 
(PGJ2) can also affect cell function in a PPARγ independent manner [25]. 
PPARs were first cloned as nuclear receptors that mediate the effects on gene 
transcription of synthetic compounds called peroxisome proliferators. 
Upregulation of PPARγ reduces expression of several mediators of inflammation 
including IL-6 [26]. However, responses of cells to PPAR ligands can be due to 
activation of PPAR or can be PPAR independent [27] actions, which appear to be 
cell and stimulus, and perhaps, ligand specific. It is not unlikely that PPARγ 
activation by AjA contributes to the therapeutic effect of the cannabinoid. 
However, it appears from the studies presented here that the anti IL-6 action of 
AjA exhibited in vitro is not due to PPARγ activation. 
The precise mechanism whereby AjA suppresses IL-6 production by 
activated human MDM is not clear. Suppression by AjA of activation of the 
transcription factor NFκB (Stebulis, et al, unpublished) might be important to 
suppression of inflammatory cytokines by AjA. T lymphocytes activated by IL-6 in 
the synovium of patients with RA can activate human monocyte/macrophages to 
induce expression of inflammatory cytokines and chemokines by NFκB 
dependent and independent mechanisms [28]. It is of interest then, that AjA 
induces apoptosis of T cells [29], and suppresses activation of NFκB (J. Stebulis, 
et al. unpublished).  In addition, T lymphocytes in the joints of RA patients are 
resistant to apoptosis [30]. IL-6 rescues T cells from entering apoptosis in vitro 
[31], and suppression of T cell apoptosis in vivo leads to autoimmune arthritis in 
mice [32]. 
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Inflammation is a well-orchestrated process designed to combat infection 
and prevent tissue injury. Like other cytokines, IL-6 can be defined as a 
modulating factor that balances initiation and resolution of inflammation. In 
diseases characterized by chronic inflammation, it appears that suppression of 
IL-6 prevents tissue injury [33]. It is likely that AjA acts in vivo on several targets 
to suppress immune mediated inflammation and tissue injury. 
 Of course, it is difficult to correlate results of experiments done in vitro with 
studies done in vivo in animal models. However, the evidence from animal 
studies [12] and experiments done in vitro which indicate that AjA suppresses 
monocyte IL-1β production [17], enhances T cell apoptosis [29], and suppresses 
production of matrix metalloproteinases [34], and results presented here suggest 
that AjA may have value for the treatment of joint inflammation in patients with 
RA, osteoarthritis, and SLE.  Successful therapy of joint tissue injury and of 
autoimmune disease will require modification of several aspects of host defense 
responses with agents that can be given safely for long periods of time.  
Nonpsychoactive cannabinoid acids meet those criteria. 
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Figure 1. IL-6 release from human MDM. Cells exposed to AjA for 60 min, then 
stimulated 18hr with 10ng/ml LPS. IL-6 in supernatants measured by ELISA. 
Values are means of 3 experiments. All samples assayed in triplicate. Error bars 
are sd for 3 experiments. *p=0.03; **p=0.01, ***p=0.005, all vs. 0µM AjA. 
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Figure 2. IL-6 gene expression in human MDM. Cells exposed to AjA for 60 min., 
then stimulated 4hr with 10ng/ml LPS. Steady state levels of cellular IL-6 mRNA 
measured by the hybridization/colorimetric assay. Error bars are sd for 3 
experiments. *p< 0.03, **p=0.02, all vs. 0µM AjA. 
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APPENDIX 
Systemic lupus erythematosus (SLE) is a chronic, autoimmune disease 
predominantly affecting women of childbearing age. A common disease 
characteristic is that of continued remissions and relapses. At early stages, the 
disease can be difficult to diagnose, but hallmarks of the condition include 
antinuclear antibodies (98% of patients) and/or anti-double strand DNA (50% - 
80% of patients) [36]. Arthritis is also common among patients with SLE. 
Interferons are cytokines that were discovered to contribute to the 
resistance of viral infection. Their influence extends to cell proliferation, 
differentiation, survival of mature lymphocytes, and they have a central role in the 
immune response against infections [37]. Interferon-alpha (IFN-α) is involved in 
viral and innate immunity; and the adaptive immune response is mediated by 
interferon-gamma (IFN-γ) [38, 39]. IFN-γ has been found to play a key role in the 
development of both autoantibodies and nephritis in mice [40]. High levels of 
IFN-γ and IFN-α have been found in sera of some SLE patients [41] and levels of 
the cytokines correlate with disease activity [36, 42]. Thus, inhibition of pro-
inflammatory cytokine production, specifically IL-6, IFN-γ and IFN-α, was 
investigated as a treatment strategy. 
After showing that AjA (Figure A) can reduce IL-6 levels in normal 
volunteers, its effects on patients with SLE were studied. AjA has been shown to 
have a high potency with a lack of ulcerogenicity and a low dependence liability. 
Thus, it may be a good drug candidate for treatment of SLE by reducing the 
production of the aforementioned cytokines. 
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Figure A. Structure of Ajulemic Acid 
 
Peripheral blood mononuclear cells (PBMC) were isolated from blood of 
SLE patients by Ficoll-Hypaque density gradient centrifugation and suspended in 
RPMI-2% FBS. The cells were separated into 6-well plates and incubated 
overnight at 5% CO2 in a 37ºC humidified incubator. For all experiments, cells 
were exposed to AjA for 60 min. For analysis of IL-6, IFN-α and IFN-γ levels in 
supernatants, PBMC were stimulated for 18hr with 10µM phytohaemagglutinin 
(PHA). Incubating for 4hr with Compound B (3M R848, TLR7, 20mM in DMSO) 
was used as an alternate stimulation method to experimentally determine IFN-α 
supernatant levels. IL-6, IFN-γ, and IFN-α levels in supernatants were measured 
by enzyme-linked immunosorbent assay (ELISA, R&D Systems).  
Release of IL-6 from PBMC stimulated with PHA in vitro was suppressed 
by AjA in a dose dependent manner (Figure B). As shown in Figures C and D, 
stimulation of IFN-α by PHA and Compound B was not achieved. IFN-α levels 
were somewhat reduced, but without consistency. Similar to IL-6 results, levels of 
IFN-γ were also suppressed by AjA in a dose dependent manner (Figure E). 
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Figure B. IL-6 release from PBMC isolated from blood of SLE patient AB. Cells 
exposed to AjA for 60 min., then stimulated for 18hr with 10µM PHA. IL-6 in 
supernatants measured by ELISA. 
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Figure C. IFN-α release from PBMC isolated from blood of SLE patient AB. Cells 
exposed to AjA for 60 min., then stimulated for 18hr with 10µM PHA. IFN-α in 
supernatants measured by ELISA. 
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Figure D. IFN-α release from PBMC isolated from blood of SLE patient LP. Cells 
exposed to AjA for 60 min., then stimulated for 4hr with Compound B (1/250). 
IFN-α in supernatants measured by ELISA. 
 
 
Figure E. IFN-γ release from PBMC isolated from blood of SLE patient AB. Cells 
exposed to AjA for 60 min., then stimulated for 18hr with 10µM PHA. IFN-γ in 
supernatants measured by ELISA. 
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Figures B, C and E represent data from one experiment.  The dose-
dependent reduction shown in figures B and E was not observed in all samples 
tested.  Common treatments for SLE such as non-steroidal anti-inflammatory 
drugs (NSAIDs), corticosteroids, or anti-malarial medications [35] may have 
contributed to the variability of experimental results. If a patient is taking 
immunosuppressive medications, it is more difficult to obtain functional immune 
cells for study in culture. In addition, variations in levels of disease activity may 
also have affected the results of these experiments. 
 Ajulemic acid has the capacity to reduce levels of IL-6 and IFN-γ in a dose 
dependent manner. The reduction of these cytokines may correlate with a 
reduction in disease activity in SLE patients.  The effects that AjA has on the 
interferon-inducible gene expression signature in patients with SLE should be 
investigated.  Dysregulated expression of the genes in the IFN pathway has been 
observed in patients with SLE. Drugs that target this pathway may have 
considerable therapeutic benefits [38]. 
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Figure B.1 IL-6 release from PBMC isolated from blood of an SLE patient. Cells 
exposed to AjA for 60 min., then stimulated for 18hr with 10µM PHA. IL-6 in 
supernatants measured by ELISA. 
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Figure B.2 IL-6 release from PBMC isolated from blood of a normal volunteer. 
Cells exposed to AjA for 60 min., then stimulated for 18hr with 10µM PHA. IL-6 in 
supernatants measured by ELISA. 
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Figure B.3 IL-6 release from PBMC isolated from blood of an SLE patient. Cells 
exposed to AjA for 60 min., then stimulated for 18hr with 10µM PHA. IL-6 in 
supernatants measured by ELISA. 
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Figure B.4 IL-6 release from PBMC isolated from blood of an SLE patient. Cells 
exposed to AjA for 60 min., then stimulated for 18hr with 10µM PHA. IL-6 in 
supernatants measured by ELISA. 
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Figure B.5 IL-6 release from PBMC isolated from blood of a normal volunteer. 
Cells exposed to AjA for 60 min., then stimulated for 18hr with 10µM PHA. IL-6 in 
supernatants measured by ELISA. 
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Figure B.6 IL-6 release from PBMC isolated from blood of an SLE patient. Cells 
exposed to AjA for 60 min., then stimulated for 18hr with 10µM PHA. IL-6 in 
supernatants measured by ELISA. 
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Figure B.7 IL-6 release from PBMC isolated from blood of a normal volunteer. 
Cells exposed to AjA for 60 min., then stimulated for 18hr with 10µM PHA. IL-6 in 
supernatants measured by ELISA. 
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Figure B.8 IL-6 release from PBMC isolated from blood of an SLE patient. Cells 
exposed to AjA for 60 min., then stimulated for 18hr with 10µM PHA. IL-6 in 
supernatants measured by ELISA. 
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Figure B.9 IL-6 release from PBMC isolated from blood of a normal volunteer. 
Cells exposed to AjA for 60 min., then stimulated for 18hr with 10µM PHA. IL-6 in 
supernatants measured by ELISA. 
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Figure B.10 IL-6 release from PBMC isolated from blood of a normal volunteer. 
Cells exposed to AjA for 60 min., then stimulated for 18hr with 10µM PHA. IL-6 in 
supernatants measured by ELISA. 
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Figure B.11 IL-6 release from PBMC isolated from blood of an SLE patient. Cells 
exposed to AjA for 60 min., then stimulated for 18hr with 10µM PHA. IL-6 in 
supernatants measured by ELISA. 
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Figure C.1 IFN-α release from PBMC isolated from blood of a normal volunteer. 
Cells exposed to AjA for 60 min., then stimulated for 18hr with 10µM PHA. IFN-α 
in supernatants measured by ELISA. 
25 
SLE Patient (MV) 12Oct06
76
105
82
135
82 90 82
68
0
20
40
60
80
100
120
140
160
Control AjA (3) AjA (10) AjA (30)
AjA Concentration (micromolar)
To
ta
l I
FN
a 
(p
g/
m
l)
NS
PHA
Figure C.2 IFN-α release from PBMC isolated from blood of an SLE patient. 
Cells exposed to AjA for 60 min., then stimulated for 18hr with 10µM PHA. IFN-α 
in supernatants measured by ELISA. 
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Figure C.3 IFN-α release from PBMC isolated from blood of a normal volunteer. 
Cells exposed to AjA for 60 min., then stimulated for 18hr with 10µM PHA. IFN-α 
in supernatants measured by ELISA. 
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Figure C.4 IFN-α release from PBMC isolated from blood of an SLE patient. 
Cells exposed to AjA for 60 min., then stimulated for 18hr with 10µM PHA. IFN-α 
in supernatants measured by ELISA. 
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Figure C.5 IFN-α release from PBMC isolated from blood of an SLE patient. 
Cells exposed to AjA for 60 min., then stimulated for 18hr with 10µM PHA. IFN-α 
in supernatants measured by ELISA. 
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Figure D.1 IFN-α release from PBMC isolated from blood of an SLE patient. 
Cells exposed to AjA for 60 min., then stimulated for 4hr with Compound B 
(1/250). IFN-α in supernatants measured by ELISA. 
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Figure D.2 IFN-α release from PBMC isolated from blood of an SLE patient. 
Cells exposed to AjA for 60 min., then stimulated for 4hr with Compound B 
(1/250). IFN-α in supernatants measured by ELISA. 
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Figure D.3 IFN-α release from PBMC isolated from blood of an SLE patient. 
Cells exposed to AjA for 60 min., then stimulated for 4hr with Compound B 
(1/250). IFN-α in supernatants measured by ELISA. 
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Figure D.4 IFN-α release from PBMC isolated from blood of normal volunteer. 
Cells exposed to AjA for 60 min., then stimulated for 4hr with Compound B 
(1/250). IFN-α in supernatants measured by ELISA. 
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Figure E.1 IFN-γ release from PBMC isolated from blood of a normal volunteer. 
Cells exposed to AjA for 60 min., then stimulated for 18hr with 10µM PHA. IFN-γ 
in supernatants measured by ELISA. 
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Figure E.2 IFN-γ release from PBMC isolated from blood of an SLE patient. 
Cells exposed to AjA for 60 min., then stimulated for 18hr with 10µM PHA. IFN-γ 
in supernatants measured by ELISA. 
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Figure E.3 IFN-γ release from PBMC isolated from blood of a normal volunteer. 
Cells exposed to AjA for 60 min., then stimulated for 18hr with 10µM PHA. IFN-γ 
in supernatants measured by ELISA. 
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Figure E.4 IFN-γ release from PBMC isolated from blood of a normal volunteer. 
Cells exposed to AjA for 60 min., then stimulated for 18hr with 10µM PHA. IFN-γ 
in supernatants measured by ELISA. 
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Figure E.5 IFN-γ release from PBMC isolated from blood of an SLE patient. 
Cells exposed to AjA for 60 min., then stimulated for 18hr with 10µM PHA. IFN-γ 
in supernatants measured by ELISA. 
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Figure E.6 IFN-γ release from PBMC isolated from blood of a normal volunteer. 
Cells exposed to AjA for 60 min., then stimulated for 18hr with 10µM PHA. IFN-γ 
in supernatants measured by ELISA. 
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Figure E.7 IFN-γ release from PBMC isolated from blood of an SLE patient. 
Cells exposed to AjA for 60 min., then stimulated for 18hr with 10µM PHA. IFN-γ 
in supernatants measured by ELISA. 
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Figure E.8 IFN-γ release from PBMC isolated from blood of an SLE patient. 
Cells exposed to AjA for 60 min., then stimulated for 18hr with 10µM PHA. IFN-γ 
in supernatants measured by ELISA. 
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Figure E.9 IFN-γ release from PBMC isolated from blood of an SLE patient. 
Cells exposed to AjA for 60 min., then stimulated for 18hr with 10µM PHA. IFN-γ 
in supernatants measured by ELISA. 
 
Normal Volunteer (RGR) 18Jan07
22
48
39
0
20
40
60
Control AjA
Concentration of AjA (micromolar)
To
ta
l I
FN
g 
(p
g/
m
l)
NS
PHA
 
Figure E.10 IFN-γ release from PBMC isolated from blood of a normal volunteer. 
Cells exposed to AjA for 60 min., then stimulated for 18hr with 10µM PHA. IFN-γ 
in supernatants measured by ELISA. 
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Figure E.11 IFN-γ release from PBMC isolated from blood of an SLE patient. 
Cells exposed to AjA for 60 min., then stimulated for 18hr with 10µM PHA. IFN-γ 
in supernatants measured by ELISA. 
